UNSPSC 51402310: Tandospirone citrate

This classification denotes a serotonin agonist and anxiolytic with the molecular formula C21H29N5O2.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0R8E9BWM4J, chemically known as 4,7-methano-1h-isoindole-1,3(2h)-dione, hexahydro-2-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-, (3aalpha,4beta,7beta,7aalpha)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) but more generally known as tandospirone citrate, which bears US NIH Compound Identifier 60558.

UNSPSC 51402310 Tandospirone citrate is a Commodity code for a specific pharmaceutical active ingredient; however, the recent state and local opportunities posted under this code do not reflect procurement of tandospirone citrate itself. Instead, issuing bodies are soliciting naloxone, opioid-reversal medications, safe drug deactivation systems, and generic multi-source pharmaceuticals through cooperative purchasing vehicles and direct county health procurement. The mismatch suggests either misclassification in the source data or that tandospirone citrate procurement, if it occurs at the state or local level, generates minimal recent activity. The kinds of entities soliciting pharmaceutical products under this code include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). Work actually being bought spans supply agreements for emergency medications and overdose-reversal products, direct-to-manufacturer pharmacy benefit arrangements, and generic pharmaceuticals distributed through established wholesaler networks.

Recent representative opportunities show activity concentrated in the South and upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries, a two-year term with one-year renewal option, and response due July 26, 2023. The Texas Health and Human Services Commission released RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, with no formal award timeline specified in that exploratory phase. MMCAP, administered by Minnesota's Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products serving participating state and local facilities, responses due March 26, 2026, with awarded vendors becoming effective July 1, 2026 through authorized wholesalers including Cencora, Cardinal Health, and Morris & Dickson. None of these solicitations specifically name tandospirone citrate as a required product.